No Data
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Heron Therapeutics, Inc. (NASDAQ:HRTX) shares have had a really impressive month, gaining 31% after a shaky period beforehand.
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Pleasing Signs As A Number Of Insiders Buy Heron Therapeutics Stock
Express News | Heron Therapeutics Announces Prior Approval Supplement Submission To FDA For ZYNRELEF VAN
TrytosaveabitOP : Before EOY ((((. Heron Anticipates FDA Action on Zynrelef Within 4-6 Months ))))